Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due...
Hankyung.com introduces: RGT Accelerates Global Expansion of SIRBOT targeting North America, Europe, and Emerging Markets
SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- RGT (Robot Global Team), a leading South Korean service robotics solutions company, has initiated a significant global market expansion with its AI-driven autonomous serving robot, SIRBOT. In a...